Clusterin attenuates the development of renal fibrosis

Journal of the American Society of Nephrology

Volumn 23, Issue 1, 2012, Pages 73-85

  Jung, Gwon Soo ^a   Kim, Mi Kyung ^a   Jung, Yun A ^a   Kim, Hye Soon ^a   Park, In Sun ^b   Min, Bon Hong ^c   Lee, Ki Up ^d   Kim, Jung Guk ^e   Park, Keun Gyu ^e   Lee, In Kyu ^e  

^a Keimyung University School of Medicine   (South Korea)

^b Inha University   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Kyungpook National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CLUSTERIN; COLLAGEN TYPE 1; COMPLEMENTARY DNA; FIBRONECTIN; GREEN FLUORESCENT PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HISTOLOGY; HORMONE RELEASE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY TUBULE EPITHELIUM; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UNILATERAL URETERAL OBSTRUCTION; UPREGULATION; URETER OBSTRUCTION;

EID: 84862923695     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011010048     Document Type: Article

References (51)

1. Ha H, Lee HB: Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol 14[Suppl 3]: S246-S249, 2003 (Pubitemid 36903934)
2. Chen S, Jim B, Ziyadeh FN: Diabetic nephropathy and transforming growth factor-beta: Transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 23: 532-543, 2003 (Pubitemid 38030087)
3. Verrecchia F, Mauviel AJ: Transforming growth factor-beta signaling through the Smad pathway: Role in extracellular matrix gene expression and regulation. J Invest Dermatol 118: 211-215, 2002 (Pubitemid 34158472)
4. Ihn H: Pathogenesis of fibrosis: Role of TGF-beta and CTGF. Curr Opin Rheumatol 14: 681-685, 2002
5. Hills CE, Squires PE: TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 31: 68-74, 2010
6. Hill C, Flyvbjerg A, Grønbaek H, Petrik J, Hill DJ, Thomas CR, Sheppard MC, Logan A: The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 141: 1196-1208, 2000 (Pubitemid 32260463)
7. Hong SW, Isono M, Chen S, Iglesias-De LaCruz MC, Han DC, Ziyadeh FN: Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smadsignalingpathway in the db/dbmouse. Am J Pathol 158: 1653-1663, 2001
8. Cheng J, Grande JP: Transforming growth factor-beta signal transduction and progressive renal disease. Exp Biol Med (Maywood) 227: 943-956, 2002 (Pubitemid 36008302)
9. Klahr S, Morrissey J: Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283: F861-F875, 2002 (Pubitemid 35192452)
10. Chevalier RL, Forbes MS, Thornhill BA: Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75: 1145-1152, 2009
11. Krag S, Danielsen CC, Carmeliet P, Nyengaard J, Wogensen L: Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease. Kidney Int 68: 2651-2666, 2005 (Pubitemid 43251011)
12. Zhou A, Ueno H, Shimomura M, Tanaka R, Shirakawa T, Nakamura H, Matsuo M, Iijima K: Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int 64: 92-101, 2003 (Pubitemid 36714161)
13. Hwang M, Kim HJ, Noh HJ, Chang YC, Chae YM, Kim KH, Jeon JP, Lee TS, Oh HK, Lee YS, Park KK: TGF-beta 1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction. Exp Mol Pathol 81: 48-54, 2006 (Pubitemid 43946855)
14. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, Mihaly J, Prager GW: Plasminogen activator inhibitor 1: Physiological and pathophysiological roles. News Physiol Sci 17: 56-61, 2002
15. Ma LJ, Fogo AB: PAI-1 and kidney fibrosis. Front Biosci 14: 2028-2041, 2009
16. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA: A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112: 379-388, 2003 (Pubitemid 38063766)
17. Oda T, Jung YO, Kim HS, Cai X, López-Guisa JM, Ikeda Y, Eddy AA: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60: 587-596, 2001 (Pubitemid 32678902)
18. Matsuo S, López-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA, Zhang G, Eddy AA: Multifunctionality of PAI-1 in fibrogenesis: Evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 67: 2221-2238, 2005 (Pubitemid 41623383)
19. Ghosh AK, Vaughan DE: PAI-1 in tissue fibrosis [published online ahead of print April 4, 2011]. J Cell Physiol doi: 10.1002/jcp.22783
20. Calero M, Rostagno A, Frangione B, Ghiso J: Clusterin and Alzheimer's disease. Subcell Biochem 38: 273-298, 2005
21. Trougakos IP, Gonos ES: Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 34: 1430-1448, 2002 (Pubitemid 35245400)
22. Trougakos IP, Gonos ES: Chapter 9: Oxidative stress in malignant progression: The role of Clusterin, a sensitive cellular biosensor of free radicals. Adv Cancer Res 104: 171-210, 2009
23. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG:Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23: 2298-2304, 2004 (Pubitemid 38496784)
24. Gautier JC, Riefke B, Walter J, Kurth P, Mylecraine L, Guilpin V, Barlow N, Gury T, Hoffman D, Ennulat D, Schuster K, Harpur E, Pettit S: Evaluation of novel biomarkers of nephrotoxicity in two strains of rat treated with Cisplatin. Toxicol Pathol 38: 943-956, 2010
25. Davis JW 2nd, Goodsaid FM, Bral CM, Obert LA, Mandakas G, Garner CE 2nd, Collins ND, Smith RJ, Rosenblum IY: Quantitative gene expression analysis in a nonhuman primate model of antibiotic-induced nephrotoxicity. Toxicol Appl Pharmacol 200: 16-26, 2004 (Pubitemid 39286670)
26. Huang Q, Dunn RT 2nd, Jayadev S, DiSorbo O, Pack FD, Farr SB, Stoll RE, Blanchard KT: Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol Sci 63: 196-207, 2001 (Pubitemid 32982793)
27. Ishii A, Sakai Y, Nakamura A: Molecular pathological evaluation of clusterin in a rat model of unilateral ureteral obstruction as a possible biomarker of nephrotoxicity. Toxicol Pathol 35: 376-382, 2007 (Pubitemid 46450078)
28. Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, Grenet O, Pantano S, Moulin P, Wahl D, Mahl A, End P, Staedtler F, Legay F, Carl K, Laurie D, Chibout SD, Vonderscher J, Maurer G: Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 28: 463-469, 2010
29. Girton RA, Sundin DP, Rosenberg ME: Clusterin protects renal tubular epithelial cells from gentamicin-mediated cytotoxicity. Am J Physiol Renal Physiol 282: F703-F709, 2002 (Pubitemid 34654518)
30. Schwochau GB, Nath KA, Rosenberg ME: Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int 53: 1647-1653, 1998 (Pubitemid 28243748)
31. Rosenberg ME, Girton R, Finkel D, Chmielewski D, Barrie A 3rd, Witte DP, Zhu G, Bissler JJ, Harmony JA, Aronow BJ: Apolipoprotein J/clusterin prevents a progressive glomerulopathy of aging. Mol Cell Biol 22: 1893-1902, 2002 (Pubitemid 34175004)
32. Yamada K, Hori Y, Hanafusa N, Okuda T, Nagano N, Choi-Miura NH, Couser WG, Miyata T, Kurokawa K, Fujita T, Nangaku M: Clusterin is upregulated in glomerular mesangial cells in complement-mediated injury. Kidney Int 59: 137-146, 2001 (Pubitemid 32055222)
33. Javelaud D, Mauviel A: Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles. Int J Biochem Cell Biol 36: 1161-1165, 2004 (Pubitemid 38515657)
34. Huang Y, Noble NA: PAI-1 as a target in kidney disease. Curr Drug Targets 8: 1007-1015, 2007 (Pubitemid 47578149)
35. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP: Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 58: 1841-1850, 2000
36. Docherty NG, O'Sullivan OE, Healy DA, Fitzpatrick JM, Watson RW: Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol 290: F4-F13, 2006
37. Misseri R, Meldrum KK: Mediators of fibrosis and apoptosis in obstructive uropathies. Curr Urol Rep 6: 140-145, 2005
38. Mao H, Li Z, Zhou Y, Li Z, Zhuang S, An X, Zhang B, Chen W, Nie J, Wang Z, Borkan SC, Wang Y, Yu X: HSP 72 attenuates renal tubular cell apoptosis and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 295: F202-F214, 2008
39. Barreira AL, Takiya CM, Castiglione RC, Maron-Gutierrez T, Barbosa CM, Ornellas DS, Verdoorn KS, Pascarelli BM, Borojevic R, Einicker-Lamas M, Leite M Jr, Morales MM, Vieyra A: Bone marrow mononuclear cells attenuate interstitial fibrosis and stimulate the repair of tubular epithelial cells after unilateral ureteral obstruction. Cell Physiol Biochem 24: 585-594, 2009
40. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA: A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 19: 329-338, 2008 (Pubitemid 351240654)
41. Zhang G, Kernan KA, Collins SJ, Cai X, López-Guisa JM, Degen JL, Shvil Y, Eddy AA: Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: Role of plasmin-activated signals. J Am Soc Nephrol 18: 846-859, 2007 (Pubitemid 46434501)
42. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA: Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 67: 1297-1307, 2005 (Pubitemid 40463106)
43. Reddy KB, Karode MC, Harmony AK, Howe PH: Interaction of transforming growth factor beta receptors with apolipoprotein J/clusterin. Biochemistry 35: 309-314, 1996 (Pubitemid 26036436)
44. Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S, Djeu JY: Induction of clusterin by AKT - Role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther 9: 1831-1841, 2010
45. Jun HO, Kim DH, Lee SW, Lee HS, Seo JH, Kim JH, Kim JH, Yu YS, Min BH, Kim KW: Clusterin protects H9c2 cardiomyocytes from oxidative stress-induced apoptosis via Akt/GSK-3b signaling pathway. Exp Mol Med 43: 53-61, 2011
46. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA: Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278: 11590-11600, 2003 (Pubitemid 36792721)
47. Lee KB, Jeon JH, Choi I, Kwon OY, Yu K, You KH: Clusterin, a novel modulator of TGF-beta signaling, is involved in Smad2/3 stability. Biochem Biophys Res Commun 366: 905-909, 2008
48. Kim HJ, Yoo EK, Kim JY, Choi YK, Lee HJ, Kim JK, Jeoung NH, Lee KU, Park IS, Min BH, Park KG, Lee CH, Aronow BJ, Sata M, Lee IK: Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler Thromb Vasc Biol 29: 1558-1564, 2009
49. McLaughlin L, Zhu G, Mistry M, Ley-Ebert C, Stuart WD, Florio CJ, Groen PA, Witt SA, Kimball TR, Witte DP, Harmony JA, Aronow BJ: Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J Clin Invest 106: 1105-1113, 2000
50. Yamashita S, Maeshima A, Kojima I, Nojima Y: Activin A is a potent activator of renal interstitial fibroblasts. J Am Soc Nephrol 15: 91-101, 2004 (Pubitemid 38020701)
51. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ: Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem 266: 23048-23052, 1991 (Pubitemid 21908758)